NO330715B1 - Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum. - Google Patents

Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum. Download PDF

Info

Publication number: NO330715B1
Authority: NO; Norway
Prior art keywords: interferon; alpha; weeks; patients; hcv
Prior art date: 1998-05-15

Application number

NO20005755A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005755D0 (no

NO20005755L (no

Inventor

Janice K Albrecht

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

2000-11-14

Publication date

2011-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO330715(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-11-14 Application filed by Schering Corp filed Critical Schering Corp

2000-11-14 Publication of NO20005755D0 publication Critical patent/NO20005755D0/no

2001-01-12 Publication of NO20005755L publication Critical patent/NO20005755L/no

2011-06-20 Publication of NO330715B1 publication Critical patent/NO330715B1/no

Links

238000011282 treatment Methods 0.000 title claims description 141
108010047761 Interferon-alpha Proteins 0.000 title claims description 83
102000006992 Interferon-alpha Human genes 0.000 title claims description 83
230000003612 virological effect Effects 0.000 title claims description 75
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims description 71
229960000329 ribavirin Drugs 0.000 title claims description 71
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims description 71
210000002966 serum Anatomy 0.000 title claims description 33
208000020403 chronic hepatitis C virus infection Diseases 0.000 title claims description 14
239000000825 pharmaceutical preparation Substances 0.000 title claims description 11
238000002360 preparation method Methods 0.000 title description 2
102100040018 Interferon alpha-2 Human genes 0.000 claims description 25
108010079944 Interferon-alpha2b Proteins 0.000 claims description 25
102000014150 Interferons Human genes 0.000 claims description 23
108010050904 Interferons Proteins 0.000 claims description 23
230000000840 anti-viral effect Effects 0.000 claims description 20
229940079322 interferon Drugs 0.000 claims description 20
208000015181 infectious disease Diseases 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 11
230000003442 weekly effect Effects 0.000 claims description 10
238000003753 real-time PCR Methods 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000002648 combination therapy Methods 0.000 description 105
230000004044 response Effects 0.000 description 100
230000002459 sustained effect Effects 0.000 description 86
229940065638 intron a Drugs 0.000 description 72
238000009097 single-agent therapy Methods 0.000 description 36
108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
238000001574 biopsy Methods 0.000 description 25
230000006872 improvement Effects 0.000 description 25
230000000694 effects Effects 0.000 description 23
239000000902 placebo Substances 0.000 description 21
229940068196 placebo Drugs 0.000 description 21
238000011529 RT qPCR Methods 0.000 description 18
208000006454 hepatitis Diseases 0.000 description 16
208000018191 liver inflammation Diseases 0.000 description 15
238000000034 method Methods 0.000 description 15
208000005176 Hepatitis C Diseases 0.000 description 14
230000009265 virologic response Effects 0.000 description 13
208000006154 Chronic hepatitis C Diseases 0.000 description 11
208000010710 hepatitis C virus infection Diseases 0.000 description 11
238000012317 liver biopsy Methods 0.000 description 11
238000007477 logistic regression Methods 0.000 description 10
210000004185 liver Anatomy 0.000 description 9
239000000203 mixture Substances 0.000 description 9
241000700605 Viruses Species 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
206010016654 Fibrosis Diseases 0.000 description 7
238000000729 Fisher's exact test Methods 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 7
230000007882 cirrhosis Effects 0.000 description 7
208000019425 cirrhosis of liver Diseases 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
238000010606 normalization Methods 0.000 description 7
238000010839 reverse transcription Methods 0.000 description 7
108010078049 Interferon alpha-2 Proteins 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
-1 polyethylene Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
238000007476 Maximum Likelihood Methods 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960003507 interferon alfa-2b Drugs 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
102100023915 Insulin Human genes 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229920000233 poly(alkylene oxides) Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
IWUCXVSUMQZMFG-SHXFMUIJSA-N 1-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1C1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-SHXFMUIJSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
VVLAIYIMMFWRFW-UHFFFAOYSA-N 2-hydroxyethylazanium;acetate Chemical compound CC(O)=O.NCCO VVLAIYIMMFWRFW-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001227713 Chiron Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
206010019837 Hepatocellular injury Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
231100000437 hepatocellular injury Toxicity 0.000 description 1
230000008935 histological improvement Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940124622 immune-modulator drug Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229950000038 interferon alfa Drugs 0.000 description 1
229960003521 interferon alfa-2a Drugs 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000002665 ion therapy Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000003041 necroinflammatory effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20005755A 1998-05-15 2000-11-14 Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum. NO330715B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7956698A	1998-05-15	1998-05-15
PCT/US1999/007037 WO1999059621A1 (en)	1998-05-15	1999-05-13	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (3)

Publication Number	Publication Date
NO20005755D0 NO20005755D0 (no)	2000-11-14
NO20005755L NO20005755L (no)	2001-01-12
NO330715B1 true NO330715B1 (no)	2011-06-20

Family

ID=22151354

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20005755A NO330715B1 (no)	1998-05-15	2000-11-14	Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum.

Country Status (23)

Country	Link
EP (3)	EP2305287A1 (es)
JP (2)	JP5281726B2 (es)
KR (1)	KR100694345B1 (es)
CN (1)	CN1230198C (es)
AR (1)	AR019551A1 (es)
AT (1)	ATE216591T1 (es)
AU (2)	AU766597B2 (es)
BR (1)	BR9910505A (es)
CA (1)	CA2331823A1 (es)
CZ (1)	CZ300540B6 (es)
DE (1)	DE69901321T2 (es)
DK (1)	DK0956861T3 (es)
ES (1)	ES2172288T3 (es)
HK (1)	HK1021131A1 (es)
HU (1)	HU230432B1 (es)
IL (3)	IL139220A0 (es)
MY (1)	MY129244A (es)
NO (1)	NO330715B1 (es)
NZ (1)	NZ507621A (es)
PT (1)	PT956861E (es)
SK (1)	SK288038B6 (es)
TW (1)	TWI277424B (es)
WO (1)	WO1999059621A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003507322A (ja) *	1998-12-18	2003-02-25	シェリング・コーポレーション	リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
CZ20022112A3 (cs) *	1999-12-23	2003-05-14	Ribapharm Inc.	Prostředky a způsoby, týkající se L-nukleosidů, L-nukleotidů, a jejich analog
JP4536194B2 (ja) *	2000-02-17	2010-09-01	大日本住友製薬株式会社	安定な注射用製剤
CA2747325A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko)	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
AU2002213343A1 (en) *	2000-10-18	2002-04-29	Schering Corporation	Ribavirin-pegylated interferon alfa HCV combination therapy
EP1536839B1 (en) *	2001-11-09	2010-09-15	Intarcia Therapeutics, Inc	Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
US7662798B2 (en)	2002-06-28	2010-02-16	Idenix Pharmaceuticals, Inc.	2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MY140819A (en)	2002-06-28	2010-01-29	Idenix Caymans Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7824851B2 (en)	2002-11-15	2010-11-02	Idenix Pharmaceuticals, Inc.	2′-branched nucleosides and Flaviviridae mutation
US20050049204A1 (en) *	2003-03-28	2005-03-03	Otto Michael J.	Compounds for the treatment of flaviviridae infections
EP1651271A4 (en) *	2003-04-01	2006-11-08	Intermune Inc	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS
JP2006523655A (ja) *	2003-04-17	2006-10-19	アレストレーディングソシエテアノニム	重症急性呼吸器症候群（ｓａｒｓ）におけるインターフェロンベータ
PT2604620T (pt)	2003-05-30	2016-08-18	Gilead Pharmasset Llc	Analogos de nucleósido fluorados modificados
JP2006527268A (ja) *	2003-06-09	2006-11-30	ゲノムインスティチュートオブシンガポール	臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
NZ545159A (en) *	2003-08-13	2009-03-31	Smith Howard J & Ass Pty Ltd	Method of treating viral infections
AR045870A1 (es) *	2003-10-11	2005-11-16	Vertex Pharma	Terapia de combinacion para la infeccion de virus de hepatitis c
EP1809301B1 (en)	2004-09-14	2019-11-06	Gilead Pharmasset LLC	2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
TWI437990B (zh) *	2004-10-29	2014-05-21	Vertex Pharma	Vx-950之醫藥用途
UA100840C2 (ru)	2006-01-09	2013-02-11	РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си.	Композиция для лечения вирусного гепатита
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
AU2008279087A1 (en)	2007-07-25	2009-01-29	Biolex Therapeutics, Inc.	Controlled release interferon drug products and treatment of HCV infection using same
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
AU2009329917B2 (en)	2008-12-23	2016-03-31	Gilead Pharmasset Llc	Nucleoside analogs
SG194404A1 (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Synthesis of purine nucleosides
AR074897A1 (es)	2008-12-23	2011-02-23	Pharmasset Inc	Fosforamidatos de nucleosidos
EP2427213B1 (en)	2009-05-08	2015-04-01	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
PT2609923T (pt)	2010-03-31	2017-08-30	Gilead Pharmasset Llc	Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
KR20140035305A (ko) *	2010-10-05	2014-03-21	노파르티스 아게	C형 간염 바이러스 감염의 새로운 치료법
EP2646453A1 (en)	2010-11-30	2013-10-09	Gilead Pharmasset LLC	Compounds
KR20200006177A (ko) *	2011-03-02	2020-01-17	제롬 쉔타그	단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
PE20141056A1 (es)	2011-09-16	2014-09-05	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
MX351816B (es)	2013-01-31	2017-10-30	Gilead Pharmasset Llc	Formulacion de combinacion de dos compuestos antivirales.
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211771A (en)	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4492537A (en)	1982-12-10	1985-01-08	Awerkamp John B	Fluid-operated oil or water well pump
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja)	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
US5711944A (en)	1993-11-10	1998-01-27	Enzon, Inc.	Interferon polymer conjugates
US5766582A (en)	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
DK0858343T3 (da) *	1995-11-02	2004-05-10	Schering Corp	Kontinuerlig lavdosis cytokininfusionsterapi
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
TW517067B (en)	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
EP1011743B1 (en)	1997-08-13	2011-07-27	Boston Scientific Limited	Loading and release of water-insoluble drugs
ATE230999T1 (de) *	1997-09-21	2003-02-15	Schering Corp	Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infection

1999
- 1999-05-13 CZ CZ20004177A patent/CZ300540B6/cs not_active IP Right Cessation
- 1999-05-13 EP EP10181927A patent/EP2305287A1/en not_active Withdrawn
- 1999-05-13 JP JP2000549285A patent/JP5281726B2/ja not_active Expired - Lifetime
- 1999-05-13 HU HU0103423A patent/HU230432B1/hu unknown
- 1999-05-13 EP EP99303729A patent/EP0956861B1/en not_active Expired - Lifetime
- 1999-05-13 SK SK1710-2000A patent/SK288038B6/sk not_active IP Right Cessation
- 1999-05-13 IL IL13922099A patent/IL139220A0/xx unknown
- 1999-05-13 DE DE69901321T patent/DE69901321T2/de not_active Expired - Lifetime
- 1999-05-13 CA CA002331823A patent/CA2331823A1/en not_active Abandoned
- 1999-05-13 CN CNB998085960A patent/CN1230198C/zh not_active Expired - Lifetime
- 1999-05-13 MY MYPI99001891A patent/MY129244A/en unknown
- 1999-05-13 AU AU38600/99A patent/AU766597B2/en not_active Withdrawn - After Issue
- 1999-05-13 TW TW088107774A patent/TWI277424B/zh not_active IP Right Cessation
- 1999-05-13 AT AT99303729T patent/ATE216591T1/de active
- 1999-05-13 WO PCT/US1999/007037 patent/WO1999059621A1/en active Application Filing
- 1999-05-13 ES ES99303729T patent/ES2172288T3/es not_active Expired - Lifetime
- 1999-05-13 KR KR1020007012784A patent/KR100694345B1/ko not_active IP Right Cessation
- 1999-05-13 BR BR9910505-5A patent/BR9910505A/pt not_active Application Discontinuation
- 1999-05-13 DK DK99303729T patent/DK0956861T3/da active
- 1999-05-13 PT PT99303729T patent/PT956861E/pt unknown
- 1999-05-13 EP EP01130613A patent/EP1213029A1/en not_active Withdrawn
- 1999-05-14 AR ARP990102303A patent/AR019551A1/es unknown
- 1999-11-20 HK HK99105377A patent/HK1021131A1/xx not_active IP Right Cessation
2000
- 2000-10-18 NZ NZ507621A patent/NZ507621A/xx not_active IP Right Cessation
- 2000-10-23 IL IL139220A patent/IL139220A/en not_active IP Right Cessation
- 2000-11-14 NO NO20005755A patent/NO330715B1/no not_active IP Right Cessation
2005
- 2005-10-10 AU AU2005220271A patent/AU2005220271B9/en not_active Expired
2010
- 2010-07-27 IL IL207259A patent/IL207259A/en not_active IP Right Cessation
2011
- 2011-04-07 JP JP2011085606A patent/JP2011173898A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
BR9910505A (pt)	2001-01-02
WO1999059621A1 (en)	1999-11-25
JP5281726B2 (ja)	2013-09-04
AU766597B2 (en)	2003-10-16
CZ20004177A3 (cs)	2001-04-11
AU2005220271B2 (en)	2005-11-03
HUP0103423A3 (en)	2003-11-28
DE69901321D1 (de)	2002-05-29
ATE216591T1 (de)	2002-05-15
IL139220A0 (en)	2001-11-25
HU230432B1 (hu)	2016-06-28
IL207259A (en)	2016-08-31
AU2005220271A1 (en)	2005-11-03
TWI277424B (en)	2007-04-01
NZ507621A (en)	2002-11-26
CN1230198C (zh)	2005-12-07
EP0956861A1 (en)	1999-11-17
CN1309568A (zh)	2001-08-22
AU3860099A (en)	1999-12-06
DK0956861T3 (da)	2002-07-01
HK1021131A1 (en)	2000-06-02
IL207259A0 (en)	2010-12-30
ES2172288T3 (es)	2002-09-16
DE69901321T2 (de)	2002-12-12
CZ300540B6 (cs)	2009-06-10
SK288038B6 (en)	2013-01-02
EP0956861B1 (en)	2002-04-24
CA2331823A1 (en)	1999-11-25
KR20010043624A (ko)	2001-05-25
JP2002515453A (ja)	2002-05-28
KR100694345B1 (ko)	2007-03-12
EP1213029A1 (en)	2002-06-12
AU2005220271B8 (en)	2010-11-18
JP2011173898A (ja)	2011-09-08
NO20005755D0 (no)	2000-11-14
HUP0103423A2 (hu)	2002-01-28
AR019551A1 (es)	2002-02-27
PT956861E (pt)	2002-08-30
EP2305287A1 (en)	2011-04-06
SK17102000A3 (sk)	2001-05-10
MY129244A (en)	2007-03-30
NO20005755L (no)	2001-01-12
AU2005220271B9 (en)	2010-12-09
IL139220A (en)	2013-02-28

Publication	Publication Date	Title
NO330715B1 (no)	2011-06-20	Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum.
US6472373B1 (en)	2002-10-29	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en)	2001-01-09	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
AU749924B2 (en)	2002-07-04	Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20020127203A1 (en)	2002-09-12	Ribavirin-pegylated interferon alfa HCV combination therapy
EP1140143A2 (en)	2001-10-10	Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en)	2004-11-30	Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (en)	2000-06-29	Ribavirin-interferon alfa induction hcv combination therapy
MXPA00011198A (es)	2001-07-31	Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han recibido tratamiento antiviral que tienen infeccion por hepatitis c cronica
MXPA98007284A (es)	1999-09-20	Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
AU2005218024A1 (en)	2005-10-27	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Legal Events

Date	Code	Title	Description
2012-09-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US
2019-06-11	MK1K	Patent expired

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2019-06-11

MK1K

Patent expired